Researches showed that topotecan, as a TOP1 inhibitor, can alleviate LPS-induced ALI by regulating NF-κB signaling pathway [33]; the activity of TOP1 can be inhibited by chemotherapeutic drugs to suppress the genes, which are regulated to cytokine and NF-κB [32]. The gene discussed is TOP1; the disease is acute respiratory distress syndrome.